Tumour-targeted chemotherapy with immunoconjugates of calicheamicin

Expert Opinion on Biological Therapy

Volumn 4, Issue 9, 2004, Pages 1445-1452

  Damle, Nitin K ^a  

^a Oncology Discovery Research   (United States)

Author keywords

Calicheamicin; Cancer; Chemotherapy; Monoclonal antibody; Tumour targeted

Indexed keywords

ANTIBODY CONJUGATE; CALICHEAMICIN; CD22 ANTIGEN; CD33 ANTIGEN; CMB 401; CMC 544; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; MUCIN 1; NATURAL PRODUCT; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANOREXIA; ANTIBODY SPECIFICITY; ANTIBODY TARGETED CHEMOTHERAPY; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER THERAPY; CELL DEATH; CHILL; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DNA BINDING; DNA STRAND BREAKAGE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FEVER; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPOTENSION; LIVER TOXICITY; MICROMONOSPORA; MICROMONOSPORA ECHINOSPORA; MONOTHERAPY; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; REVIEW; SEPSIS; THROMBOCYTOPENIA; TUMOR SPECIFIC CYTOTOXICITY; TUMOR TARGETED CHEMOTHERAPY; TUMOR XENOGRAFT; VOMITING;

AGED; AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, NEOPLASM; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DNA DAMAGE; DRUG DELIVERY SYSTEMS; ENEDIYNES; FEMALE; HEMATOLOGIC DISEASES; HEMATOLOGIC NEOPLASMS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOCONJUGATES; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MICROMONOSPORA; MICROMONOSPORA ECHINOSPORA; MUS MUSCULUS;

EID: 4544350808     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.9.1445     Document Type: Review

References (52)

1. TRAIL P, BIANCHI A: Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol. (1999) 11:584-588.
2. DUBOWCHIK G, WALKER M: Receptor-mediated and enzyme-dependent targeting of cytotoxic anti-cancer drugs. Pharmacol. Ther. (1999) 83:67-123.
3. KREITMAN RJ: Immunotoxins in cancer therapy. Curr. Opin. Immunol. (1999) 11(5):577-578.
4. GOLDENBERG DM: Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol. Immunother. (2003) 52(5):281-296.
5. MAIESE WM, LECHEVALIER MP, LECHEVALIER HA et al.: Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties. J. Antibiotics (1989) 42(4):558-563.
6. THORSON J, SIEVERS E, AHLERT J a al.: Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr. Pharmaceut. Des. (2000) 6:1841-1879.
7. LEE M, DUNNE T, CHANG C et al.: Calicheamicins, a novel family of antibiotics. Structural elucidations of Calicheamicins. J. Am. Chem. Soc. (1992) 114:985-987.
8. 1: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science (1988) 240:1198-1201.
9. HINMAN LM, HAMANN PR, WALLACE R et al.: Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. (1993) 53:3336-3342.
10. HIN MAN L, HAMANN P, UPESLACIS J: Preparation of conjugates to monoclonal antibodies. In: Endiyne Antibiotics as Antitumor Agents. Borders D, Doyle T (Eds), Marcel Decker, New York, USA (1995):87-106.
11. HAMANN P, HINMAN L, BEYER C et al.: An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. (2002) 13:40-46.
12. HAMANN P, HINMAN L, HOLLANDER I et al.: Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. (2002) 13:47-58.
13. DIJOSEPH J, ARMELLINO D, BOGHAERT E et al.: Antibody-targeted chemotherapy with CMC-544, a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood (2004) 103:1807-1814.
14. DIJOSEPH JF, POPPLEWELL A, TICKLE S et al.: Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol. Immunother. (2004) (In Press).
15. BOGHAERT E, SRIDHARAN L, ARMELLINO D et al.: A calicheamicin conjugate that targets Lewis Y selectively destroys Lewis Y-positive human carcinoma cells and xenografts. Clin. Cancer Res. (2004) 10(13):4538-4549.
16. ADAMS GP, SCHIER R, MCCALL AM et al.: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. (2001) 61(12):4750-4755.
17. TENCER J, FRICKI-M, ÖQUIST BW, ALM P, RIPPE B: Size selectivity of the glomerular barrier to high molecular weight proteins: upper size limitations of the shunt pathways. Kidney Int. (1998) 53:709-715.
18. BROSS P, BEITZ J, CHEN G et al.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. (2001) 7:1490-1496.
19. BERGER M, LEOPOLD L, DOWELL J, KORTH-BRADLEY J, SHERMAN M: Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Invest. New Drugs (2002) 20:395-406.
20. ANDREWS R, SINGER J, BERNSTEIN I: Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J. Exp. Med. (1989) 169:1721-1731.
21. SIEVERS E, APPLEBAUM F, SPIELBERGER R et al.: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A Phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 93:3678-3684.
22. SIEVERS E, LARSON R, STADMAUER E et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. (2001) 19:3244-3254.
23. LARSON R, BOOGAERTS M, ESTEY E et al.: Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia (2002) 16:1627-1636.
24. SIEVERS E, LARSON R, ESTEY E et al.: Final report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematopoietic stem cell transplantation. Blood (2002) 100:89a.
25. LINENBERGER M, HONG T, FLOWERS D et al.: Multidrug-resistance phenotype and clinical responses to gemruzumab ozogamicin. Blood (2001) 98:988-994.
26. NAITO K, TAKESHITA A, SHIGENO K et a.: Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemic cell lines but is inactive on P-glycoprotein-expressing sublines. Leukemia (2000) 14:1436-1443.
27. MATSUI H, TAKESHITA A, NAITO K et al.: Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia (2002) 16:813-819.
28. WALTER R, LINENBERGER M, HONG T, RADEN W, BERNSTEIN I: Multidrug resistance protein (MRP) attenuates gemtuzumab ozogamicin (GO)-induced cytotoxicity in acute myeloid leukemia (AML). Blood (2003) 100(11):224b-225b.
29. GILES F, KANTARJIAN H, KORNBLAU S et al.: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer (2001) 92:406-413.
30. NEUMEISTER P, EIBL M, ZINKE-CERWENKA W, SCARPATETTI M, SILL H, LINKESCH W: Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann. Hematol. (2001) 80:119-120.
31. RAJVANSHI P, SHULMAN H, SIEVERS E, MCDONALD G: Hepatic sinusoidal onstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood (2002) 99:2310-2314.
32. CHEN A, LUGER S, SICKLES C et al. Gemtuzumab ozogamicin (Mylotarg™) therapy for relapsed AML after hematopoetic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant. (2002) 9:23-28.
33. DOLL C, YARBRO J: Vascular toxicity associated with antineoplastic agents. Semin. Oncol. (1992) 19:580-596.
34. RICHARDSON P, GUINAN E: Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol. (2001) 106:57-68.
35. ERBA H, STADTMAUER E, LARSON R et al.: Results of a multivariate analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin. Blood (2002) 100:339a.
36. WADLEIGH M, RICHARDSON PG, ZAHRIEH D et al.: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood (2003) 102(5):1578-1582.
37. ALVARADO Y, TSIMBERIDOU A, KANTARJIAN H et al.: Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother. Pharmacol. (2003) 51:87-90.
38. TSIMERIDOU A, ESTEY E, CORTES J et al.: Gemtuzumab, fludarabine, cytarabine, and cydosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer (2003) 97(6):1481-1487.
39. BACCARANI M, DURRANT S, LINKESCH W et al.: Preliminary report of a Phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabinc in patients with acute myeloid leukemia. Blood (2002) 100(11):341a.
40. DE ANGELO D, SCHIFFER C, AMREIN P et al.: Interim analysis of a Phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients < 60 years old with untreated acute myeloid leukemia. Blood (2002) 100(11):198a-199a.
41. ESTEY E, GILES F, BERAN M et al.: Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood (2002) 99:4222-4224.
42. PETTI M, PINAZZI MB, DIVERIO D et al.: Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br. J. Haematol. (2001) 115:63-65.
43. VON MENSDORFF-POUILLY S, SNIJDEWINT FG, VERSTRAETEN AA, VERHEIJEN RH, KENEMANS P: Human MUC1 mucin: a multifaceted glycoprotein. Int. J. Markers (2000) 15(4):343-356.
44. DAVIES Q, PERKINS AC, FRIER M, WATSON S, LALANI E, SYMONDS EM: The effect of circulating antigen on the biodistribution of the engineered human antibody hCTMO1 in a nude mice model. Eur. J. Nucl. Med. (1997) 24(2):206-209.
45. DAVIES Q, PERKINS AC, ROOS JC et al.: An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma. Br. J. Obstet. Gynaecol. (1999) 106(1):31-37.
46. VAN HOF AC, MOLTHOFF CF, DAVIES Q: Biodistribution of (111l)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose. Cancer Res. (1996) 56(22):5179-5185.
47. GILLESPIE AM, BROADHEAD TJ, CHAN SY et al.: Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann. Oncol. (2000) 11(6):735-741.
48. CHAN SY, GORDON AN, COLEMAN RE a al.: A Phase II study of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol. Immunother. (2003) 52(4):243-248.
49. CROCKER PR, VARKI A: Siglecs, sialic acis, and innate immunity. Trends Immunol. (2001) 22:337-342.
50. LI JL, SHEN GL, GHETIE MA et al.: The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cell. Immunol. (1989) 118:85-99.
51. HANNA R, ONG G, MATTES M: Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Cancer Res. (1996) 56:3062-3068.
52. DIJOSEPH JF, GOAD ME, DOUGHER MM et al.: Potent and specific antitumour efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin. Cancer Res. (2004) (In Press).